Super Generics Market: Industry Trends and Global Forecasts, Till 2035: Distribution by Therapeutic Area

Super Generics Market: Industry Trends and Global Forecasts, Till 2035: Distribution by Therapeutic Area

In the pharmaceutical domain the super generic drugs represent the enhanced versions of original pharmaceuticals that have lost their patent exclusivity. These refined pharmacological interventions are often termed as complex generics or value-added generics and serve as generic alternatives to their branded counterparts. Notably, in 2022, the US FDA sanctioned over 32,000 generic drug products, with 91% of all US prescriptions being filled with generics. These improved super generics hold the potential for advancements in drug delivery, manufacturing processes, and reformulation techniques. This value-added segment operates within a framework of ongoing innovation, offering promising opportunities in the pharmaceutical market. Super generic drugs are granted a form of marketing exclusivity, typically for 3 to 7 years, allowing developers to achieve relatively high profit margins as compared to the conventional generics. Regulatory bodies such as the FDA (in the US) or the EMA (in Europe) scrutinize these drugs and grant approval for their entry in the super generics market.

Developing super generic drugs entails rigorous research and development to ensure their safety, efficacy, and quality. Industry stakeholders invest in extensive preclinical and clinical studies to establish bioequivalence or therapeutic equivalence with the reference brand-name drug. As regulatory agencies worldwide greenlight more generic drugs, competition in the industry is expected to intensify. The primary consequence of this heightened competition is a decrease in the cost of generics, leading to reduced profit margins for developers. Hence, to sustain growth in the off-patent drug market, companies are progressively adopting innovative drug alteration techniques to create value-added medicinal products with better commercial prospects. Retail and online pharmacies offer a wide array of generic options, empowering consumers to lower healthcare expenses. Moreover, in numerous European countries, pharmacists have the authority to substitute brand-name prescriptions with generic equivalents unless otherwise specified by healthcare. providers.

Key Market Segments

Therapeutic Area

Cardiovascular Disorders

Metabolic Disorders

Neurological Disorders

Oncological Disorders

Respiratory Disorders

Other Disorders

Route of Administration

Intravenous

Oral

Subcutaneous

Others

Type of Molecule

Small

Other Molecules

Type of Small Molecule

Generics

Other Small Molecule

Type of Product

Aerosols

Capsules

Prefilled Syringes

Tablets

Vials

Other Products

Geography

North America

Europe

Asia-Pacific

Rest of the World

Research Coverage:

A summary of super generics technologies, including details on various pertinent parameters such as the type of drug modification, technology type, molecules formulated/delivered, route of administration, and type of value addition. This encompasses information on technology providers offering platforms/solutions for super generic drug development, including their year of establishment, company size (in terms of the number of employees), and headquarters location.

An insightful analysis of the competitiveness of the technologies compiled in our database, considering pertinent parameters including supplier power (based on the company size of technology providers) and technology competitiveness, such as the type of molecule, impact on drug properties, and route of administration.

Detailed profiles of prominent technology developers involved in this domain are provided, offering an overview of the company, its financial information where available, technology portfolio, recent advancements, and future outlook.

A compilation of marketed generics that, in our assessment, are poised to be developed as super generics in the near future, derived from a thorough analysis considering various pertinent parameters. These parameters include the current annual cost of treatment of the parent drug, year of patent expiry, sales revenues generated in the year prior to patent expiry, target therapeutic area, and the number of competitor (generic) drugs available in the market.

Comprehensive case studies are presented for five approved supergeneric drugs, encompassing an overview of the drug along with details on the original/parent drug, the value proposition offered by the supergeneric version, pricing strategies adopted by the developer where available, annual sales revenues of the supergeneric and parent drug if available, and key learnings/takeaways from each case study.

A discourse on associated trends, key drivers, and challenges within a SWOT framework, which are anticipated to influence the evolution of the industry, accompanied by a Harvey ball analysis to illustrate the relative impact of each SWOT parameter on the overall super generics market.

A thorough assessment of the current market size, existing opportunity, and the future growth potential of the super generics market over the next decade is conducted. Drawing from various parameters, including likely adoption trends, we have formulated an informed estimate on the market evolution during the forecast period from 2024 to 2035. The report also includes an analysis of the likely distribution of current and forecasted opportunities within the super generics market. Additionally, to accommodate future uncertainties and enhance the robustness of our model, three forecast scenarios—conservative, base, and optimistic—are provided, representing different trajectories of growth in the super generics market.

Key Benefits of Buying this Report

The report offers market leaders and newcomers valuable insights into revenue estimations for both the overall market and its sub-segments.

Stakeholders can utilize the report to enhance their understanding of the competitive landscape, allowing for improved business positioning and more effective go-to-market strategies.

The report provides stakeholders with a pulse on the Super Generics Market, furnishing them with essential information on significant market drivers, barriers, opportunities, and challenges.

Leading Market Companies

Accord Healthcare

Alcon Laboratories

Ascendia Pharmaceuticals

Azurity Pharmaceuticals

Baxter

CritiTech

Crossject

DelSiTech

Dr. Reddy’s Laboratories

Exela Pharma Sciences

Harrow Health

Heron Therapeutics

Hikma Pharmaceuticals

Intellipharmaceutics International

Kashiv BioSciences

Latitude Pharmaceuticals

Mayne Pharma

meda pharmaceuticals

Neurelis

Rubicon Research

Sun Pharmaceutical industries

Taiwan Liposome Company

Tesa Labtec

Teva Pharmaceutical